Within the first few years of initiating injection drug use, over half of people who inject drugs (PWID) will become infected with hepatitis C virus (HCV). Preventing hepatitis transmission among PWID will require a comprehensive approach to harm reduction services including increased access to syringe services programs (SSPs), Medication Assisted Treatment (MAT), screening and diagnosis in outreach settings with culturally competent providers, and treatment without any restrictions.
To address such issues, the National Alliance of State and Territorial AIDS Directors (NASTAD) established a coalition of stakeholders, the Hepatitis Testing Partnership to increase hepatitis testing and linkage to care for PWID, as well as increase the uptake of other HCV testing recommendations across the nation.
If you are interested in joining the partnership, please complete this form; if you have any questions about this group, please contact Alyssa Kitlas, Manager, Hepatitis.
